Obefazimod (ABX464) for Moderate-to-Severe Crohn’s disease: clinical development of a novel oral therapeutic approach

Therapeutic advances in inflammatory bowel disease have accelerated over the past decade; however, progress has not been uniform across disease subtypes. Crohn’s disease continues to lag behind ...